Arcus Biosciences (RCUS) Non-Current Assets (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Non-Current Assets of $153.0 million for Q1 2026, down 9.47% year-over-year from $169.0 million in Q1 2025, and up 15.91% quarter-over-quarter from $132.0 million in Q4 2025.
Arcus Biosciences (RCUS) Non-Current Assets (2017 - 2026) Analysis & Trends
Arcus Biosciences' Non-Current Assets history runs 10 years deep, the most recent figure standing at $153.0 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 9.47% year-over-year to $153.0 million; the TTM figure through Mar 2026 stood at $531.0 million (down 18.81% YoY), while the FY2025 annual figure was $132.0 million, down 1.49% from the prior year.
- Non-Current Assets for Q1 2026 stood at $153.0 million, up from $132.0 million in the prior quarter.
- The five-year high for Non-Current Assets was $309.0 million in Q3 2023, with the low at $117.0 million in Q3 2025.
- The 5-year median for Non-Current Assets is $233.0 million (2022), against an average of $207.1 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets soared 199.41% in 2022, then plunged 49.24% in 2024.
- Arcus Biosciences' Non-Current Assets stood at $233.0 million in 2022, then climbed by 13.3% to $264.0 million in 2023, then slumped by 49.24% to $134.0 million in 2024, then dropped by 1.49% to $132.0 million in 2025, then grew by 15.91% to $153.0 million in 2026.
- Business Quant data shows RCUS's Non-Current Assets at $153.0 million in Q1 2026, $132.0 million in Q4 2025, and $117.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 168.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 168.00 Mn |
| Mar 31, 2026 | 153.00 Mn |
| Dec 31, 2025 | 132.00 Mn |
| Sep 30, 2025 | 117.00 Mn |
| Jun 30, 2025 | 129.00 Mn |
| Mar 31, 2025 | 169.00 Mn |
| Dec 31, 2024 | 134.00 Mn |
| Sep 30, 2024 | 173.00 Mn |
| Jun 30, 2024 | 178.00 Mn |
| Mar 31, 2024 | 236.00 Mn |
| Dec 31, 2023 | 264.00 Mn |
| Sep 30, 2023 | 309.00 Mn |
| Jun 30, 2023 | 234.00 Mn |
| Mar 31, 2023 | 239.00 Mn |
| Dec 31, 2022 | 233.00 Mn |
| Sep 30, 2022 | 292.71 Mn |
| Jun 30, 2022 | 249.30 Mn |
| Mar 31, 2022 | 279.20 Mn |
| Dec 31, 2021 | 330.00 Mn |
| Sep 30, 2021 | 294.00 Mn |